TrialCancer letters2025

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.

Chi Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.